Lunglmayr G
Hospital Mistelbach, Austria.
Anticancer Drugs. 1995 Aug;6(4):508-13. doi: 10.1097/00001813-199508000-00003.
The efficacy and tolerability of Casodex, a new non-steroidal antiandrogen, were studied in 267 patients with advanced prostate cancer. All patients received Casodex, 50 mg daily, as monotherapy. The objective response rate was 55.5% and the subjective response rate was 56.1%. The most common adverse events were the expected pharmacological effects of breast tenderness, gynecomastia and hot flushes. No other adverse events were reported in more than 5% of patients. There was minimal occurrence of impotence, loss of libido and diarrhea. The results show that Casodex 50 mg is effective and well tolerated in the treatment of advanced prostate cancer.
对267例晚期前列腺癌患者研究了新型非甾体抗雄激素药物康士得（Casodex）的疗效和耐受性。所有患者接受每日50毫克康士得单药治疗。客观缓解率为55.5%，主观缓解率为56.1%。最常见的不良事件是预期的药理作用，如乳房压痛、男性乳房发育和潮热。超过5%的患者未报告其他不良事件。阳痿、性欲减退和腹泻的发生率极低。结果表明，50毫克康士得治疗晚期前列腺癌有效且耐受性良好。
